Topical treatment for superficial disseminated actinic porokeratosis: A Single-Blinded Comparison Between Lovastatin/Cholesterol and Lovastatin Save

Date Added
April 7th, 2020
PRO Number
Pro00096259
Researcher
Dirk Elston

List of Studies


Profiles_link
Keywords
Drug Studies, Genetics, Inflammation, Pain, Rare Diseases, Skin
Summary

The purpose of this research is to treat disseminated actinic porokeratosis (DSAP) with cholesterol/lovastatin or lovastatin alone. The goal of treatment is to decrease (DSAP) lesions after 12 weeks of treatment and compare which treatment is best.

The study is single-blinded and randomized, meaning the patients will not be told of which treatment they will receive, and the decision of which treatment they will receive will be completely random. The patient will also agree to close up photographs and clinical photographs taken of their disseminated actinic porokeratosis at the initial visit. At weeks 4, 8, and 12, the patients will complete a virtual visit. The subject will take a picture (phone camera/digital camera) of their lesions/skin markings with a measuring instrument. These photos will be shared with the investigators. Physical exam, photographs, and a review of of the subjects medical records will occur in the study. Changes in size, appearance, and pain will be monitored throughout the study.

The possible benefit of joining this study is that the treatment received may be more effective than the other study treatment or than other available treatments for DSAP, although this cannot be guaranteed.

Institution
MUSC
Recruitment Contact
Alan Snyder
9106195832
snydeala@musc.edu

Change_preferences

-- OR --

Create_login